文献速递消化道肿瘤放疗姑息放疗与转移瘤

原发灶放疗对不可切除IV期直肠或直乙交界癌生存的影响:倾向性评分匹配分析

The effect of primary tumor radiotherapy in patients with Unresectable stage IV Rectal or Rectosigmoid Cancer: a propensity score matching analysis for survival.
PubMed 文献 · Radiat Oncol · 2020-05-27

该回顾性研究纳入2008年9月至2017年9月间350例不可切除转移性直肠或直乙交界癌患者,所有患者至少接受4周期化疗,其中163例接受原发灶放疗(中位剂量56.69 Gy)。经倾向性评分匹配等多因素Cox回归分析,原发灶放疗可降低18个月死亡风险(HR 0.62, 95%CI 0.40-0.98;HR 0.70, 95%CI 0.55-0.99等)。结论认为原发灶放疗不仅可缓解症状,还可能改善生存,处方剂量可考虑59.4 Gy/33次或60 Gy/30次。

要点

  • 原发灶放疗组中位OS为20.07个月,未放疗组为17.33个月(P=0.002)。
  • 多因素Cox回归显示原发灶放疗降低18个月死亡风险(HR 0.62, 95%CI 0.40-0.98)。
  • 原发灶放疗处方剂量可考虑59.4 Gy/33次或60 Gy/30次。

核心结论

  • 与未接受原发灶放疗的IV期直肠或直乙交界癌患者相比,接受原发灶放疗者死亡风险更低。
  • 原发灶放疗处方剂量(59.4 Gy/33次或60 Gy/30次)不仅可缓解症状,还可能改善不可手术转移性直肠或直乙交界癌患者的生存。

研究设计与样本

  • 回顾性研究,纳入2008年9月至2017年9月单中心350例不可切除转移性直肠或直乙交界癌患者。
  • 所有患者至少接受4周期化疗,按是否接受原发灶放疗分为两组,163例接受放疗,中位放疗剂量56.69 Gy(50.4-60)。
  • 采用Kaplan-Meier法粗略比较生存,以18个月生存率为结局变量,经倾向性评分匹配(PSM)后行多因素Cox回归分析。

主要发现

  • 中位随访21个月,全部350例患者中位化疗7周期(范围4-12),163例(46.67%)因局部症状接受原发灶放疗。
  • Kaplan-Meier曲线显示原发灶放疗组较未放疗组有显著总生存(OS)优势(20.07 vs 17.33个月;P=0.002)。
  • 多因素Cox回归(协变量调整后)显示原发灶放疗降低18个月死亡风险(HR 0.62, 95%CI 0.40-0.98)。
  • PSM后多因素Cox回归显示HR 0.79(95%CI 0.93-1.45)。
  • IPTW分析显示HR 0.70(95%CI 0.55-0.99),PS校正模型分析显示HR 0.74(95%CI 0.59-0.94)。

关键数值与推荐

  • 原发灶放疗中位剂量56.69 Gy(范围50.4-60 Gy)。
  • 结论中提及原发灶放疗处方剂量可考虑59.4 Gy/33次或60 Gy/30次。

临床怎么用

  • 对于不可切除的IV期直肠或直乙交界癌患者,在至少4周期化疗基础上,可考虑对原发灶行放疗以缓解局部症状并可能改善生存。
  • 放疗处方剂量可参考59.4 Gy/33次或60 Gy/30次。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate the impact of primary tumor radiotherapy on survival in patients with unresectable metastatic rectal or rectosigmoid cancer. METHODS: From September 2008 to September 2017, 350 patients with unresectable metastatic rectal or rectosigmoid cancer were retrospectively reviewed in our center. All patients received at least 4 cycles of chemotherapy and were divided into two groups according to whether they received primary tumor radiotherapy. A total of 163 patients received primary tumor radiotherapy, and the median radiation dose was 56.69 Gy (50.4-60). Survival curves were estimated with the Kaplan-Meier method to roughly compare survival between the two groups. Subsequently, the 18-month survival rate was used as the outcome variable for this study. This study mainly evaluated the impact of primary tumor radiotherapy on the survival of these patients through a series of multivariate Cox regression analyses after propensity score matching (PSM). RESULTS: The median follow-up time was 21 months. All 350 patients received a median of 7 cycles of chemotherapy (range 4-12), and 163 (46.67%) patients received primary tumor radiotherapy for local symptoms. The Kaplan-Meier survival curves showed that the primary tumor radiotherapy group had a significant overall survival (OS) advantage compared to the group without radiotherapy (20.07 vs 17.33 months; P = 0.002). In this study, the multivariate Cox regression analysis after adjusting for covariates, multivariate Cox regression analysis after PSM, inverse probability of treatment weighting (IPTW) analysis and propensity score (PS)-adjusted model analysis consistently showed that primary tumor radiotherapy could effectively reduce the risk of death for these patients at 18 months (HR: 0.62, 95% CI 0.40-0.98; HR: 0.79, 95% CI: 0.93-1.45; HR: 0.70, 95% CI 0.55-0.99 and HR: 0.74, 95% CI: 0.59-0.94). CONCLUSION: Compared with patients with stage IV rectal or rectosigmoid cancer who did not receive primary tumor radiotherapy, those who received primary tumor radiotherapy had a lower risk of death. The prescription dose (59.4 Gy/33 fractions or 60 Gy/30 fractions) of radiation for primary tumors might be considered not only to relieve symptoms improve the survival of patients with inoperable metastatic rectal or rectosigmoid cancer.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Wang G, Wang W, Jin H, et al. The effect of primary tumor radiotherapy in patients with Unresectable stage IV Rectal or Rectosigmoid Cancer: a propensity score matching analysis for survival. Radiat Oncol. 2020. PMID: 32460810. doi:10.1186/s13014-020-01574-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。